We, therefore, used human post mortem brain samples and conducted a thorough characterization of the most studied tau PTMs, namely ubiquitination, acetylation, and mono-methylation on Lysine residues, and phosphorylation on Serine and Threonine residues, using an untargeted MS approach to identify PTMs on soluble tau that would distinguish between tauopathies. The gene discussed is MAPT; the disease is tauopathy.